Circulation and degradation of GIP and GLP-1

被引:228
|
作者
Deacon, CF [1 ]
机构
[1] Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; gut hormone; incretin; dipeptidyl peptidase IV; neutral endopeptidase 24.11;
D O I
10.1055/s-2004-826160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 50 条
  • [21] Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists
    Emanuel, Ezekiel J.
    Dellgren, Johan L.
    Mccoy, Matthew S.
    Persad, Govind
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (20): : 1839 - 1842
  • [22] Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association
    Neumiller, Joshua J.
    Bajaj, Mandeep
    Bannuru, Raveendhara R.
    Mccoy, Rozalina G.
    Pekas, Elizabeth J.
    Segal, Alissa R.
    Elsayed, Nuha A.
    DIABETES CARE, 2025, 48 (02) : 177 - 181
  • [23] Intestinal CART is a regulator of GIP and GLP-1 secretion and expression
    Shcherbina, L.
    Lindqvist, A.
    Fischer, A-H Thoren
    Ahlqvist, E.
    Zhang, E.
    Falkmer, S. E.
    Renstrom, E.
    Koffert, J.
    Honka, H.
    Wierup, N.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 476 : 8 - 16
  • [24] Rate of intestinal glucose absorption and the secretion of GIP and GLP-1
    Priebe, MG
    Wachters-Hagedoorn, RE
    Holst, JJ
    Stellaard, F
    Vonk, RJ
    FASEB JOURNAL, 2005, 19 (04): : A74 - A74
  • [25] Central administration of GLP-1 and GIP decreases feeding in mice
    NamKoong, Cherl
    Kim, Min Sun
    Jang, Byeong-Tak
    Lee, Young Hee
    Cho, Young-Mm
    Choi, Hyung Jin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 490 (02) : 247 - 252
  • [26] THE INSULINOTROPIC EFFECT OF GIP AND GLP-1 IN HEALTHY AND DIABETIC SUBJECTS
    MCALOONDYKE, M
    FUKAGAWA, NK
    HABENER, J
    ANDERSEN, DK
    ELAHI, D
    REGULATORY PEPTIDES, 1992, 40 (02) : 205 - 205
  • [27] Incretin effect: GLP-1, GIP, DPP4
    Kazakos, Kyriakos
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 : S32 - S36
  • [28] Effects of an RYGB on β-Cell Sensitivity to GLP-1 and GIP examined
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (12):
  • [29] How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    Samms, Ricardo J.
    Goghlan, Matthew P.
    Sloop, Kyle W.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2020, 31 (06): : 410 - 421
  • [30] The incretin system in healthy humans: The role of GIP and GLP-1
    Hoist, Jens Juul
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 96 : 46 - 55